Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Debra Rogan"'
Autor:
Hendrik-Tobias Arkenau, Li Yan, Jolly Mazumdar, Noelia Nebot, K. Auger, Jianping Zhang, Ruth Plummer, Sarah P. Blagden, Alastair Greystoke, Jean-Charles Soria, Jerry M. Tolson, Ivana Rizzuto, Debra Rogan, Gabriel Mak, Ronald A. Fleming, Anas Gazzah
Publikováno v:
British Journal of Cancer
Background Combined focal adhesion kinase (FAK) and MEK inhibition may provide greater anticancer effect than FAK monotherapy. Methods This dose-finding phase Ib study (adaptive 3 + 3 design) determined the maximum tolerated dose (MTD) of trametinib
Autor:
Catherine E. Ellis, Michael Chisamore, Eric Angevin, Marc S. Ballas, Erminia Massarelli, Debra Rogan, Victor Moreno, Hui K Gan, Axel Hoos, Maria Vieito, Antoine Italiano, Riccardo Danielli, Arjun Vasant Balar, Courtney Henry, Frans L. Opdam, Xiao Ji, Francesco Ricci
Publikováno v:
Journal of Clinical Oncology. 39:4519-4519
4519 Background: INDUCE-1 is a first-in-human trial evaluating fela, an IgG4 ICOS agonist non-T-cell depleting mAb, as monotherapy (mono) and in combo with P. ECs include tumor types, such as UC, with high ICOS expression and immunotherapy-favorable
Autor:
Tatiana Hernandez-Guerrero, Michael Chisamore, Raid Aljumaily, Sonia Franco, Maria Vieito, Catherine E. Ellis, Ani Sarkis Balmanoukian, Christophe Le Tourneau, Courtney Henry, Debra Rogan, Danny Rischin, Axel Hoos, David C. Turner, Jose Manuel Trigo, Erminia Massarelli, Ruby Sung, Marc S. Ballas, Sapna Yadavilli
Publikováno v:
Journal of Clinical Oncology. 38:6544-6544
6544 Background: The KEYNOTE-048 study (Burtness, at al. Lancet 2019;394:1915–28) led to approval of PE in combination with 5-FU/plat for first-line (1L) treatment of head and neck squamous cell carcinoma (HNSCC). The Phase I INDUCE-1 study (NCT027
Autor:
O. Amit, A. Leighton-Swayze, M.C. Garassino, Marc S. Ballas, A. Acusta, Martin Reck, David R. Spigel, Debra Rogan, M. Schenker, S. Cousin, Axel Hoos, Adrian G. Sacher, Benjamin Besse, M. Barve, Sapna Yadavilli
Publikováno v:
Journal of Thoracic Oncology. 14:S404-S405
Autor:
Kurt R. Auger, Hendrik-Tobias Arkenau, Ruth Plummer, Alastair Greystoke, Sarah P. Blagden, Anas Gazzah, L. Yan, Ivana Rizzuto, Rajendra P. Singh, Ronald A. Fleming, Maria L Mattern, Jolly Mazumdar, Noelia Nebot, Gabriel Mak, Kevin H. Laubscher, Jean-Charles Soria, Debra Rogan, Lisa S Swartz
Publikováno v:
Journal of Clinical Oncology. 33:2593-2593
2593 Background: The focal adhesion kinase (FAK) and MAPK pathways share common upstream activators and contribute to cell proliferation, differentiation, migration and survival. Dual inhibition of...